DCI Announces Latest Release of SureLynx, the Leading Electronic Data Capture Application for Early Stage Clinical Trials
Data Capture International, Inc. (DCI), an emerging Application Service Provider that offers Electronic Data Capture (EDC) software solutions and services to pharmaceutical companies and Contract Research Organizations (CRO's) that perform Phase I (early stage) human clinical trials, announced the release of SureLynx(TM) V2.0.
MARIETTA, Ga., April 26, 2005 /PRNewswire/ -- Data Capture International, Inc. (DCI), an emerging Application Service Provider that offers Electronic Data Capture (EDC) software solutions and services to pharmaceutical companies and Contract Research Organizations (CRO's) that perform Phase I (early stage) human clinical trials, announced the release of SureLynx(TM) V2.0.
SureLynx is DCI's flagship product and consists of a software application for increasing efficiency, improving data quality, and providing standardization for the collection of data in Phase I clinical trials. In addition to the software application, state-of-the-art bar code technology and radio-frequency transmission are combined with approved clinical trial methodologies to yield a product and process that have been proven in the practical setting and provide significant advantages over other systems.
Troy W. McCall, Ph.D., President, said, "The release of SureLynx V2.0 marks an important milestone in our evolution. Our ongoing development efforts ensure that our clients will continue to use state-of-the-art technologies to gain competitive advantages in conducting early stage clinical trials."
"SureLynx is self-directed, self-checking, mobile, user-friendly, and compliant with the strict regulations set forth in 21 CFR Part 11," said Deborah Rucker, Vice President, Business Development. "Our experience, which spans more than 15 years with earlier versions, has been critical in developing the most adaptable system available in the market today."
Dr. McCall continued, "While there are numerous EDC applications available for the collection of clinical data, SureLynx is the only one designed exclusively for early stage trials. This ensures the highest quality data will be efficiently collected in a cost-competitive manner."
Company Background
Data Capture International, Inc. (DCI) was founded to enhance pharmaceutical development by providing value-added software solutions and services for Phase I clinical trials. The company's mission is to be the leading provider of automated identification and data capture technology and systems supporting pharmaceutical product development.
CONTACT: Deborah Rucker, Vice President, Business Development of DataCapture International, Inc., +1-813-654-0132, or drucker@datacaptureintl.com
Web site: www.datacaptureintl.com/
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
